Sumitomo Dainippon Pharma Co., Ltd.

Sumitomo Pharma Co., Ltd.

Manabu Kusagi

Hitoshi Ban

Futoshi Hasegawa

Shingo Tojo

Miki Hashizume

Chiang Jia Li

Hiroki Yamaguchi

Yosuke Takanashi

Nobuyuki Sawada

Tsuguteru Otsubo

Eiji Sugaru

The present invention provides a 1,4-disubstituted imidazole derivative of formula (1') wherein ring Qis optionally-substituted Caryl group, etc.; Rand Rare independently hydrogen atom, etc.; Wis optionally-substituted Calkylene group; Wis &#x2014;NRC(O)&#x2014; wherein Ris hydrogen atom or Calkyl group, etc.; ring Qis 5- to 10-membered heteroaryl group, etc.; Wis optionally-substituted Calkylene group, etc.; n is 1, 2, 3, 4, or 5; Ris independently halogen atom, optionally-substituted Calkyl group, etc.; Ris hydroxy group, etc.; and a pharmacologically acceptable salt thereof, which have a potent inhibitory effect on the sphere-forming capacity of cancer cells and are useful as an orally-available anti-tumor agent. 

1,4-disubstituted imidazole derivative

The present invention pertains to an imidazolylamide derivative represented by formula (1) that exhibits an exceptional suppressive effect on cancer cell sphere formation ability and that is useful as an antitumor agent that can be administered orally, or a pharmacologically acceptable salt thereof. [In the formula, ring Qrepresents a Caryl group or the like; m represents 0, 1, 2, 3, 4, or 5; R, independently when multiple, represent(s) a halogen atom or the like; Rand Rindependently represent a hydrogen atom or the like; Wrepresents a Calkylene group (said group may be substituted by 1-3 fluorine atoms or Ccycloalkyls); Wrepresents &#x2014;NRC(O)&#x2014; or the like (where Rrepresents a hydrogen atom or Calkyl group); and ring Qrepresents a Carylgroup or the like] 

Imidazolylamide derivative

The present invention provides a bicyclic heterocyclic amide derivative of formula (1) wherein ring Qis optionally-substituted Caryl group, etc.; Rand Rare independently hydrogen atom, etc.; Wis optionally-substituted Calkylene group; Wis &#x2014;NRC(O)&#x2014;, etc. wherein Ris hydrogen atom or Calkyl group; Cyis the following group of formula (11), etc.; ring Qis optionally-substituted benzene ring, etc.; n and m are independently 0, 1 or 2, provided that n and m are not simultaneously 0; X is NR, etc.; Ris hydrogen atom, etc.; p is 1, 2, 3, 4 or 5; Ris, independently when two or more exist, hydrogen atom, etc.; and a pharmacologically acceptable salt thereof, which have a potent inhibitory effect on the sphere-forming ability of cancer cells and are useful as an orally-available anti-tumor agent. 

Bicyclic heterocyclic amide derivative

Growing community of inventors

Osaka, Japan

Manabu Kusagi